Addex Therapeutics (ADXN) Liabilities and Shareholders Equity (2022 - 2025)
Historic Liabilities and Shareholders Equity for Addex Therapeutics (ADXN) over the last 4 years, with Q3 2025 value amounting to $9.2 million.
- Addex Therapeutics' Liabilities and Shareholders Equity fell 3475.08% to $9.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.2 million, marking a year-over-year increase of 1027.84%. This contributed to the annual value of $12.1 million for FY2024, which is 13484.77% up from last year.
- Per Addex Therapeutics' latest filing, its Liabilities and Shareholders Equity stood at $9.2 million for Q3 2025, which was down 3475.08% from $10.3 million recorded in Q2 2025.
- Addex Therapeutics' 5-year Liabilities and Shareholders Equity high stood at $19.1 million for Q1 2022, and its period low was $3.8 million during Q1 2024.
- Over the past 4 years, Addex Therapeutics' median Liabilities and Shareholders Equity value was $10.3 million (recorded in 2025), while the average stood at $10.5 million.
- Per our database at Business Quant, Addex Therapeutics' Liabilities and Shareholders Equity plummeted by 5880.71% in 2023 and then surged by 17600.8% in 2025.
- Addex Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $8.6 million in 2022, then tumbled by 39.13% to $5.2 million in 2023, then soared by 132.93% to $12.2 million in 2024, then decreased by 24.82% to $9.2 million in 2025.
- Its Liabilities and Shareholders Equity was $9.2 million in Q3 2025, compared to $10.3 million in Q2 2025 and $10.5 million in Q1 2025.